PMID-37351564 – Orforglipron Phase 2 Obesity Trial
Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023;389(10):877-888.
Quick Reference
| Property | Value |
|---|---|
| PMID | 37351564 |
| DOI | 10.1056/NEJMoa2302392 |
| Year | 2023 |
| Journal | New England Journal of Medicine |
| Study Type | RCT (Phase 2) |
| Evidence Level | II |
| Sample | n=272 adults with obesity or overweight with comorbidity (no diabetes) |
| Peptide(s) Studied | Orforglipron |
Key Findings
- At week 36, mean body weight change ranged from -9.4% to -14.7% across orforglipron dose groups vs. -2.3% with placebo
- At week 26, mean change from baseline ranged from -8.6% to -12.6% vs. -2.0% (placebo)
- The 36 mg and 45 mg doses achieved the greatest weight loss (~14.7%)
- Mean baseline body weight was 108.7 kg (BMI 37.9)
- 46-75% of orforglipron-treated participants achieved >=10% weight loss
- GI adverse events (nausea, vomiting, diarrhea) were the most common, occurring in a dose-dependent pattern
- Most GI events were mild-to-moderate and occurred during dose escalation
- No cases of pancreatitis; no medullary thyroid carcinoma signals
Study Design
Phase 2, randomised, double-blind, placebo-controlled trial. Adults with BMI >=30 (or >=27 with weight-related comorbidity) without diabetes were randomized to orforglipron at 12, 24, 36, or 45 mg once daily orally, or placebo for 36 weeks. Dose escalation occurred over the first 12-29 days depending on the dose group. Primary endpoint was percent change in body weight from baseline.
Limitations
- Phase 2 trial with modest sample size (n=272)
- 36-week duration is relatively short for chronic weight management
- No active comparator arm (no head-to-head vs. semaglutide or tirzepatide)
- GI tolerability may limit real-world adherence
- All participants were non-diabetic; efficacy in T2D assessed in a separate trial
Clinical Relevance
This landmark NEJM publication demonstrated that a non-peptide, oral, small-molecule GLP-1 RA can achieve weight loss comparable to injectable GLP-1 RAs (~15% at 36 weeks). This is paradigm-shifting for the field: if oral agents can match injectable efficacy, the barrier to entry for obesity pharmacotherapy drops dramatically. For peptide therapy practitioners, orforglipron represents a competitive threat to injectable peptides but also validates the GLP-1 pathway for weight management. Understanding orforglipron helps practitioners contextualize why patients may seek oral alternatives. NOTE: Orforglipron is NOT a peptide — it is a small molecule that activates the same GLP-1 receptor.
Related
#research #RCT #evidence-level-II #metabolic #orforglipron #investigational #oral